AgomAb Therapeutics (NASDAQ:AGMB) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of AgomAb Therapeutics (NASDAQ:AGMB) to a hold rating in a research report sent to investors on Wednesday,Zacks.com reports.

Other analysts also recently issued reports about the company. Wall Street Zen upgraded AgomAb Therapeutics to a “hold” rating in a research report on Tuesday, February 17th. Morgan Stanley began coverage on AgomAb Therapeutics in a research note on Tuesday. They set an “overweight” rating and a $28.00 price target for the company. JPMorgan Chase & Co. started coverage on shares of AgomAb Therapeutics in a research note on Tuesday. They issued an “overweight” rating and a $32.00 price objective on the stock. Finally, Leerink Partners initiated coverage on shares of AgomAb Therapeutics in a report on Tuesday. They set an “outperform” rating and a $36.00 target price for the company. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $32.00.

AgomAb Therapeutics Trading Down 3.6%

Shares of NASDAQ:AGMB opened at $13.70 on Wednesday. AgomAb Therapeutics has a 12 month low of $12.66 and a 12 month high of $17.45.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.